The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 3, 2010, Pages 133-142

  Holcakova, Jitka ^a   Tomasec, Peter ^b   Bugert, Joachim J ^b   Wang, Eddie C Y ^b   Wilkinson, Gavin W G ^b   Hrstka, Roman ^a   Krystof, Vladimir ^c   Strnad, Miroslav ^c   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHLOROQUINE; CIDOFOVIR; CYCLIN DEPENDENT KINASE INHIBITOR; IDOXURIDINE; OLOMOUCINE II; RIBAVIRIN; ROSCOVITINE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 4; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; POXVIRUS; PRIORITY JOURNAL; VACCINIA VIRUS; VIROGENESIS; VIRUS INHIBITION; VIRUS REPLICATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; IC 50; VIRAL PHENOMENA AND FUNCTIONS; VIRUS;

ANTIVIRAL AGENTS; CYCLIN-DEPENDENT KINASES; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS; PURINES; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUS REPLICATION; VIRUSES;

EID: 77649226169     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1460     Document Type: Article

References (47)

1. Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 2006; 17:293-320.
2. Meyerson M, Enders GH, Wu CL, et al. A family of human cdc2-related protein kinases. EMBO J 1992; 11:2909-2917.
3. Murray AW, Marks D. Can sequencing shed light on cell cycling? Nature 2001; 409:844-846.
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912- 1934.
5. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23:417-425.
6. Arris CE, Boyle FT, Calvert AH, et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 2000; 43:2797-2804.
7. De Azevedo WF, Leclerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243:518-526.
8. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclindependent kinases by purine analogues. Eur J Biochem 1994; 224:771-786.
9. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994; 201:589-595.
10. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-536.
11. Kryštof V, Lenobel R, Havlicek L, Kuzma M, Strnad M. Synthesis and biological activity of olomoucine II. Bioorg Med Chem Lett 2002; 12:3283-3286.
12. Kryštof V, McNae IW, Walkinshaw MD, et al. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci 2005; 62:1763-1771.
13. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60:785-789.
14. Diwan P, Lacasse JJ, Schang LM. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol 2004; 78:9352-9365.
15. Bresnahan WA, Boldogh I, Chi P, Thompson EA, Albrecht T. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997; 231:239-247.
16. Mancebo HS, Lee G, Flygare J, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997; 11:2633-2644.
17. Schang LM, Phillips J, Schaffer PA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 1998; 72:5626-5637.
18. Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002; 76:7874-7882.
19. Wang D, de la Fuente C, Deng L, et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001; 75:7266-7279.
20. Wang L, Deng L, Wu K, et al. Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors. Mol Cell Biochem 2002; 237:137-153.
21. Kudoh A, Daikoku T, Sugaya Y, et al. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J Virol 2004; 78:104-115.
22. Davido DJ, Leib DA, Schaffer PA. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0. J Virol 2002; 76:1077-1088.
23. Kapasi AJ, Spector DH. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 2008; 82:394-407.
24. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-28348.
25. Schang LM, Rosenberg A, Schaffer PA. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J Virol 1999; 73:2161-2172.
26. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999; 17:313-320.
27. Nicholl MJ, Preston CM. Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific. J Virol 1996; 70:6336-6339.
28. Sangfelt O, Erickson S, Einhorn S, Grander D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997; 14:415-423.
29. Satomoto K, Haisa M, Naomoto Y, Tanaka N, Orita K. Cyclin A and Cdk2 kinase activity are suppressed by combined treatment with tumor necrosis factor-α and interferon-α. Biochem Biophys Res Commun 1995; 213:1115-1121.
30. Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. Interferon-induces expression of cyclin-dependent kinaseinhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 1998; 16:217-225.
31. Havlicek L, Hanus J, Vesely J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997; 40:408-412.
32. Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987; 165:408-416.
33. Jacobs SC, Davison AJ, Carr S, et al. Characterization and manipulation of the human adenovirus 4 genome. J Gen Virol 2004; 85:3361-3366.
34. McSharry BP, Tomasec P, Neale ML, Wilkinson GW. The most abundantly transcribed human cytomegalovirus gene (beta 2.7) is non-essential for growth in vitro. J Gen Virol 2003; 84:2511-2516.
35. Matrosovich M, Matrosovich T, Garten W, Klenk HD. New low-viscosity overlay medium for viral plaque assays. Virol J 2006; 3:63.
36. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001; 414:322-325.
37. Simone C, Bagella L, Bellan C, Giordano A. Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene 2002; 21:4158-4165.
38. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxylterminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002; 22:4622-4637.
39. Fischer PM, Endicott J, Meijer L. Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res 2003; 5:235-248.
40. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-134.
41. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006; 11:1164-1188.
42. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000; 6:379-392.
43. Silver M, McFadden G, Wilton S, Dales S. Biogenesis of poxviruses: role for the DNA-dependent RNA polymerase II of the host during expression of late functions. Proc Natl Acad Sci U S A 1979; 76:4122-4125.
44. Yoo NK, Pyo CW, Kim Y, Ahn BY, Choi SY. Vaccinia virus-mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP. Cell Microbiol 2008; 10:583-592.
45. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis 2003; 3:79-86.
46. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-394.
47. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486.